Androgen antagonists.Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) - i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, et venales sunt a Janssen Biotech sub commercio Zytiga. Insuper, Intas pharmaceutica medicamenta mercatus est sub nomine Abiratas, Cadila Pharmacum medicamentum Abretonianum mercatus est, and Glenmark Pharmaceuticals as Abirapro.
Aceta Abiraterone probata a Civitatibus Foederatis Americae Food et Drug Administration nonis Aprilis 28, 2011. Dimissio pressa FDA referens ad periodum III clinicam probationem in qua usus abiraterone adiunctus est cum mediana superstite. 14.8 mensibus versus 10.9 menses cum placebo; studio omissus primo propter prosperos exitus.
Usus in Cancro Abiraterone acetate approbatur utendum cum cancer prostatae tractare quae metastasizavit (ad alias partes corporis). Adhibetur in aegris, quorum morbus cum aliis hormonum justo non obtinuerit.
Abiraterone etiam in curatione aliarum specierum cancri studetur.
